Jan 8 (Reuters) - Spark Therapeutics:
* SPARK THERAPEUTICS CEO SAYS PLANS TO BEGIN PROGRAM IN POMPE DISEASE
* SPARK CEO SAYS EXPECTS LUXTURNA GENE THERAPY TO BE AVAILABLE TO PATIENTS IN EUROPE IN 2019 Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)
 